Hong Kong Stock Movement | HUTCHMED (00013.HK) rises more than 4% again; sovleplenib granted orphan drug designation by the FDA for the treatment of autoimmune hemolytic anemia.
Zhitong Finance APP has learned that HUTCHMED (00013.HK) rose more than 4% again. As of press time, it was up 4.11% at HK$22.78, with a turnover of HK$39.7005 million.
Latest
